Company Overview
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Why Investors Should Care
Generates a return on equity of 26.4%, reflecting efficient use of shareholder capital.
Maintains a net profit margin of 33.7%.
Carries low leverage with a debt-to-equity ratio of 0.11.
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | - |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 26.4%.
- Excellent profit margin of 33.7%.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLNO SLNO R2KPHARMA | - | - | - | 0.00% | 2.98% | 26.38% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 32.66M | 66.02M | 91.73M | 94.60M |
| Cost of Revenue | - | - | 0 | 696.00K | 1.14M | 863.00K | 1.20M |
| Gross Profit | - | - | 0 | 31.96M | 64.88M | 90.87M | 93.41M |
| Operating Expenses | - | - | 42.78M | 37.38M | 42.16M | 50.44M | 61.64M |
| Operating Income | - | - | -42.78M | -5.42M | 22.72M | 40.43M | 31.76M |
| EBITDA | - | - | -41.91M | -2.83M | 27.91M | 45.22M | 36.72M |
| Interest Expense | - | - | 1.36M | 1.38M | 1.39M | 1.35M | 1.29M |
| Pretax Income | - | - | -43.77M | -4.71M | 26.01M | 43.36M | 34.91M |
| Tax Provision | - | - | - | - | - | - | 3.54M |
| Net Income | - | - | -43.77M | -4.71M | 26.01M | 43.36M | 31.38M |
| Diluted EPS | - | - | -0.95 | -0.09 | 0.47 | 0.80 | 0.59 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 190.41M |
| Cost of Revenue | - | - | 0 | 0 | 2.70M |
| Gross Profit | - | - | 0 | 0 | 187.71M |
| Operating Expenses | - | 25.11M | 38.67M | 184.43M | 172.75M |
| Operating Income | - | -25.11M | -38.67M | -184.43M | 14.95M |
| EBITDA | - | -22.10M | -37.03M | -173.63M | 28.38M |
| Interest Expense | - | 0 | 0 | 231.00K | 5.48M |
| Pretax Income | - | -24.07M | -38.99M | -175.85M | 20.89M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -24.07M | -38.99M | -175.85M | 20.89M |
| Diluted EPS | - | -2.87 | -2.36 | -4.38 | 0.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 26.50M | 180.69M | 330.97M | 563.83M |
| Current Assets | - | 15.65M | 171.36M | 293.89M | 355.81M |
| Cash & Equivalents | - | 14.60M | 169.68M | 87.93M | 70.11M |
| Inventory | - | - | - | 0 | 15.02M |
| Receivables | - | - | - | 0 | 28.21M |
| Total Liabilities | - | 16.15M | 23.18M | 85.86M | 113.72M |
| Current Liabilities | - | 7.31M | 11.51M | 18.75M | 61.36M |
| Long Term Debt | - | - | - | 49.83M | 49.86M |
| Total Debt | - | 155.00K | 403.00K | 52.83M | 52.55M |
| Total Equity | - | 10.35M | 157.51M | 245.11M | 450.12M |
| Shares Outstanding | - | 8.16M | 31.68M | 45.70M | 52.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -20.78M | -24.94M | -69.10M | 46.80M |
| Investing Cash Flow | - | -13.00K | 0 | -225.68M | -201.78M |
| Financing Cash Flow | - | 14.09M | 180.02M | 213.03M | 137.16M |
| Capital Expenditure | -22.00K | -13.00K | - | -218.00K | -73.00K |
| Free Cash Flow | - | -20.79M | -24.94M | -69.31M | 46.73M |
| Net Change in Cash | - | -6.70M | 155.08M | -81.75M | -17.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 98.6% |
| Operating Margin % | - | - | - | - | 7.9% |
| Net Margin % | - | - | - | - | 11.0% |
| ROE % | - | -232.6% | -24.8% | -71.7% | 4.6% |
| ROCE % | - | -130.9% | -22.9% | -59.1% | 3.0% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLNO
Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPRktKNzdBdmIyVFNtdTFvZjZoWkd0WE1XWEdfXzZ6M0FpUjF0dFRBeEktcllvbXdjZmkwZEVvbEdOVWFxS1l3UzhfUDdBNXFWQVVDbjNIamViQldxNnNkbzJCVW5WckwtNkg2QktKRjhJeHdBb0NWQVdkVDBmSDV1WmtRNGRmUFRPcVpMdV…
Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNR3prUzJSb2FmYm9LUDVBbElERnJkV0ZhZ1k5S0dkTURzYVBaT0dYWWhWZjlwRDk2ek5fdkl5bGdMaUFrOWRPdEVnQWpZd2l1TGZLcWxUV01ObzRLdUQwUENQQkQyLWdoTVRDWVYzaWVaYUU3ZkwtVGp0WUlNakkwYlRha1p6NkVleTY3Z1…
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPTExjSGFEZGRPOHlNRWE5aEcxZ01VUjZIa083bFlzTnNFVXp6U3haeFZsaXR0Q3hpa2lYajJSR09iUFhRa3p3WjJ4SExyRmhfNlduaWlvYy1CN2pFSW1ER2c4dUs4dGhCS1UwUWkwUThzTTJLMjJ4enpjMVFhQ3N2TWtRNV9ZYTZ3dzlVbS…
Soleno Therapeutics Stock Pre-Market (+9.2%): Strong Q4 Earnings Beat & Profitability - Trefis
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOU1psTEUwanVTSi05UEp6N0ZOaHFfVm1GYzRIVEJINEJHT1FuMXBoWmd6UTg2V1hiVTZBYWR4SHljaG5jd1lsTmZUWHVrZUN2blVFYlhCdUp3MUFQUUtOQldrem9NWHdmQm1Ra0RobTlvWF9zQWlfSjQ5STJxSmVQSjVKR3lLUUpaS0FPOT…
Soleno Therapeutics jumps on $2.9B all-cash buyout deal at $53/share | SLNO Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRDZXZzZJT3FaZUdTdjVuVXQ0WHVHeGV0UTFoX0QyTHI3SVJwcHpzanB3b1otVlpCVnZkWWpvV29YaXJqWms3Z3lTWVpjQ2VkcWxQTTJCZlcwcVRqcW8wdHZ4MlZuSERDcTdjeXYxQWd5RXBmRHRMaDRKb1h6TFZpS0tjeUZ2dDZmRGNQNl…
Rare disease biotech Soleno sets Feb. 25 call on 2025 results - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQcVlMYlA4VW1jUjA0bVBkbXhfLWEwLUpGWWlkREswbU9NUks2eVp1MlVCMjNpYmVsWUY0bzY1TWozQWF2cndlXzYxM0ZsRUNQdDRsRnBRRDZQTFBqYVpnc2JpeVg2WTV2VzFFZ0dHdDZnSHpwMmNWODBBVW5SbW9PSWZDNTJXeFZUNzgwNk…
SLNO — Frequently Asked Questions
What is the return on equity (ROE) of SLNO?
SLNO has a return on equity (ROE) of 26.38%. Its return on capital employed (ROCE) is 2.98%.
Is SLNO a good stock to buy?
This page provides a data-driven analysis of SLNO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.